Ar-variant–positive CTC: A surrogate for a surrogate for taxane therapy outcome?

Scott M. Dehm; Bruce Montgomery; Stephen R. Plymate

doi:10.1158/1078-0432.CCR-18-3727

Ar-variant–positive CTC: A surrogate for a surrogate for taxane therapy outcome?

Scott M. Dehm, Bruce Montgomery, Stephen R. Plymate

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880.

Original language	English (US)
Pages (from-to)	1696-1698
Number of pages	3
Journal	Clinical Cancer Research
Volume	25
Issue number	6
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-3727
State	Published - 2019

Bibliographical note

Publisher Copyright:
© 2018 American Association for Cancer Research.

Keywords

Humans
Male
Neoplastic Cells, Circulating
Prostatic Neoplasms, Castration-Resistant
RNA, Messenger
Receptors, Androgen
Taxoids

PubMed: MeSH publication types

Comment
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1158/1078-0432.CCR-18-3727

Find It

Find It at U of M Libraries

Cite this

@article{fbae63e6bfa74564b99e9f8386852764,

title = "Ar-variant–positive CTC: A surrogate for a surrogate for taxane therapy outcome?",

abstract = "Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880.",

keywords = "Humans, Male, Neoplastic Cells, Circulating, Prostatic Neoplasms, Castration-Resistant, RNA, Messenger, Receptors, Androgen, Taxoids",

author = "Dehm, {Scott M.} and Bruce Montgomery and Plymate, {Stephen R.}",

note = "Publisher Copyright: {\textcopyright} 2018 American Association for Cancer Research.",

year = "2019",

doi = "10.1158/1078-0432.CCR-18-3727",

language = "English (US)",

volume = "25",

pages = "1696--1698",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - Ar-variant–positive CTC

T2 - A surrogate for a surrogate for taxane therapy outcome?

AU - Dehm, Scott M.

AU - Montgomery, Bruce

AU - Plymate, Stephen R.

PY - 2019

Y1 - 2019

N2 - Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880.

AB - Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880.

KW - Humans

KW - Male

KW - Neoplastic Cells, Circulating

KW - Prostatic Neoplasms, Castration-Resistant

KW - RNA, Messenger

KW - Receptors, Androgen

KW - Taxoids

UR - http://www.scopus.com/inward/record.url?scp=85062994673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062994673&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-3727

DO - 10.1158/1078-0432.CCR-18-3727

M3 - Article

C2 - 30591516

AN - SCOPUS:85062994673

SN - 1078-0432

VL - 25

SP - 1696

EP - 1698

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 6

ER -

Ar-variant–positive CTC: A surrogate for a surrogate for taxane therapy outcome?

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this